Drug Profile
Defactinib - Verastem Oncology
Alternative Names: Defactinib hydrochloride; PF-04554878; PF-4554878; VS-6063Latest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Cancer Research UK; European Network of Gynaecological Oncological Trial Groups; Gynecologic Oncology Group; National Cancer Institute (USA); Pfizer; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of California, San Diego; University of Utah; Verastem; Verastem Oncology
- Class Amines; Antineoplastics; Benzamides; Fluorinated hydrocarbons; Pyrazines; Pyrimidines; Small molecules; Sulfones
- Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ovarian cancer
- Phase II Gynaecological cancer; Lymphoma; Malignant-mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Thyroid cancer; Uveal melanoma
- Phase I/II Fallopian tube cancer; Malignant melanoma; Peritoneal cancer
- No development reported Breast cancer; Cancer
Most Recent Events
- 14 Mar 2024 Verastem plans to initiate discussions with European and Japanese authorities for approval of avutometinib and defactinib combination in Ovarian cancer
- 08 Feb 2024 Phase-I/II clinical trials in Malignant melanoma(Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT06194929)
- 13 Dec 2023 Phase-III clinical trials in Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (PO) (NCT06072781)